Cargando…

Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts

BACKGROUND: While oral anticoagulants (OACs) are highly effective for ischemic stroke prevention in atrial fibrillation, intracerebral hemorrhage (ICH) remains the most feared complication of OAC. Clinical controversy remains regarding OAC resumption and its timing for ICH survivors with atrial fibr...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yan, Shoamanesh, Ashkan, Schulman, Sam, Dowlatshahi, Dar, Salman, Rustam Al-Shahi, Moldovan, Ioana Doina, Wells, Philip Stephen, AlKherayf, Fahad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784940/
https://www.ncbi.nlm.nih.gov/pubmed/29370183
http://dx.doi.org/10.1371/journal.pone.0191137
_version_ 1783295539524141056
author Xu, Yan
Shoamanesh, Ashkan
Schulman, Sam
Dowlatshahi, Dar
Salman, Rustam Al-Shahi
Moldovan, Ioana Doina
Wells, Philip Stephen
AlKherayf, Fahad
author_facet Xu, Yan
Shoamanesh, Ashkan
Schulman, Sam
Dowlatshahi, Dar
Salman, Rustam Al-Shahi
Moldovan, Ioana Doina
Wells, Philip Stephen
AlKherayf, Fahad
author_sort Xu, Yan
collection PubMed
description BACKGROUND: While oral anticoagulants (OACs) are highly effective for ischemic stroke prevention in atrial fibrillation, intracerebral hemorrhage (ICH) remains the most feared complication of OAC. Clinical controversy remains regarding OAC resumption and its timing for ICH survivors with atrial fibrillation because the balance between risks and benefits has not been investigated in randomized trials. AIMS/HYPOTHESIS: To survey the practice of stroke neurologists, thrombosis experts and neurosurgeons on OAC re-initiation following OAC-associated ICH. METHODS: An online survey was distributed to members of the International Society for Thrombosis and Haemostasis, Canadian Stroke Consortium, NAVIGATE-ESUS trial investigators (Clinicatrials.gov identifier NCT02313909) and American Association of Neurological Surgeons. Demographic factors and 11 clinical scenarios were included. RESULTS: Two hundred twenty-eight participants from 38 countries completed the survey. Majority of participants were affiliated with academic centers, and >20% managed more than 15 OAC-associated ICH patients/year. Proportion of respondents suggesting OAC anticoagulant resumption varied from 30% (for cerebral amyloid angiopathy) to 98% (for traumatic ICH). Within this group, there was wide distribution in response for timing of resumption: 21.4% preferred to re-start OACs after 1–3 weeks of incident ICH, while 25.3% opted to start after 1–3 months. Neurosurgery respondents preferred earlier OAC resumption compared to stroke neurologists or thrombosis experts in 5 scenarios (p<0.05 by Kendall’s tau). CONCLUSIONS: Wide variations in current practice exist among management of OAC-associated ICH, with decisions influenced by patient- and provider-related factors. As these variations likely reflect the lack of high quality evidence, randomized trials are direly needed in this population.
format Online
Article
Text
id pubmed-5784940
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57849402018-02-09 Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts Xu, Yan Shoamanesh, Ashkan Schulman, Sam Dowlatshahi, Dar Salman, Rustam Al-Shahi Moldovan, Ioana Doina Wells, Philip Stephen AlKherayf, Fahad PLoS One Research Article BACKGROUND: While oral anticoagulants (OACs) are highly effective for ischemic stroke prevention in atrial fibrillation, intracerebral hemorrhage (ICH) remains the most feared complication of OAC. Clinical controversy remains regarding OAC resumption and its timing for ICH survivors with atrial fibrillation because the balance between risks and benefits has not been investigated in randomized trials. AIMS/HYPOTHESIS: To survey the practice of stroke neurologists, thrombosis experts and neurosurgeons on OAC re-initiation following OAC-associated ICH. METHODS: An online survey was distributed to members of the International Society for Thrombosis and Haemostasis, Canadian Stroke Consortium, NAVIGATE-ESUS trial investigators (Clinicatrials.gov identifier NCT02313909) and American Association of Neurological Surgeons. Demographic factors and 11 clinical scenarios were included. RESULTS: Two hundred twenty-eight participants from 38 countries completed the survey. Majority of participants were affiliated with academic centers, and >20% managed more than 15 OAC-associated ICH patients/year. Proportion of respondents suggesting OAC anticoagulant resumption varied from 30% (for cerebral amyloid angiopathy) to 98% (for traumatic ICH). Within this group, there was wide distribution in response for timing of resumption: 21.4% preferred to re-start OACs after 1–3 weeks of incident ICH, while 25.3% opted to start after 1–3 months. Neurosurgery respondents preferred earlier OAC resumption compared to stroke neurologists or thrombosis experts in 5 scenarios (p<0.05 by Kendall’s tau). CONCLUSIONS: Wide variations in current practice exist among management of OAC-associated ICH, with decisions influenced by patient- and provider-related factors. As these variations likely reflect the lack of high quality evidence, randomized trials are direly needed in this population. Public Library of Science 2018-01-25 /pmc/articles/PMC5784940/ /pubmed/29370183 http://dx.doi.org/10.1371/journal.pone.0191137 Text en © 2018 Xu et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Xu, Yan
Shoamanesh, Ashkan
Schulman, Sam
Dowlatshahi, Dar
Salman, Rustam Al-Shahi
Moldovan, Ioana Doina
Wells, Philip Stephen
AlKherayf, Fahad
Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts
title Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts
title_full Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts
title_fullStr Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts
title_full_unstemmed Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts
title_short Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts
title_sort oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: global survey of the practices of neurologists, neurosurgeons and thrombosis experts
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784940/
https://www.ncbi.nlm.nih.gov/pubmed/29370183
http://dx.doi.org/10.1371/journal.pone.0191137
work_keys_str_mv AT xuyan oralanticoagulantreinitiationfollowingintracerebralhemorrhageinnonvalvularatrialfibrillationglobalsurveyofthepracticesofneurologistsneurosurgeonsandthrombosisexperts
AT shoamaneshashkan oralanticoagulantreinitiationfollowingintracerebralhemorrhageinnonvalvularatrialfibrillationglobalsurveyofthepracticesofneurologistsneurosurgeonsandthrombosisexperts
AT schulmansam oralanticoagulantreinitiationfollowingintracerebralhemorrhageinnonvalvularatrialfibrillationglobalsurveyofthepracticesofneurologistsneurosurgeonsandthrombosisexperts
AT dowlatshahidar oralanticoagulantreinitiationfollowingintracerebralhemorrhageinnonvalvularatrialfibrillationglobalsurveyofthepracticesofneurologistsneurosurgeonsandthrombosisexperts
AT salmanrustamalshahi oralanticoagulantreinitiationfollowingintracerebralhemorrhageinnonvalvularatrialfibrillationglobalsurveyofthepracticesofneurologistsneurosurgeonsandthrombosisexperts
AT moldovanioanadoina oralanticoagulantreinitiationfollowingintracerebralhemorrhageinnonvalvularatrialfibrillationglobalsurveyofthepracticesofneurologistsneurosurgeonsandthrombosisexperts
AT wellsphilipstephen oralanticoagulantreinitiationfollowingintracerebralhemorrhageinnonvalvularatrialfibrillationglobalsurveyofthepracticesofneurologistsneurosurgeonsandthrombosisexperts
AT alkherayffahad oralanticoagulantreinitiationfollowingintracerebralhemorrhageinnonvalvularatrialfibrillationglobalsurveyofthepracticesofneurologistsneurosurgeonsandthrombosisexperts